# Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients

> **NCT06343090** · NA · RECRUITING · sponsor: **Beijing GoBroad Hospital** · enrollment: 353 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia, in Relapse
- Refractory Acute Lymphoid Leukemia

## Interventions

- **DRUG:** CD19 CAR T-cell
- **DRUG:** CD22 CAR T cells
- **PROCEDURE:** hematopoietic stem-cell transplantation

## Key facts

- **NCT ID:** NCT06343090
- **Lead sponsor:** Beijing GoBroad Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-12
- **Primary completion:** 2042-12-01
- **Final completion:** 2043-09-30
- **Target enrollment:** 353 (ESTIMATED)
- **Last updated:** 2026-03-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06343090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06343090, "Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients". Retrieved via AI Analytics 2026-07-23 from https://api.ai-analytics.org/clinical/NCT06343090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*